Literature DB >> 36059987

Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

Fangyi Zhao1,2, Ziqian Cheng1,2, Jingjing Piao1,2, Ranji Cui1,2, Bingjin Li1,2.   

Abstract

Dopamine and its receptors are currently recognized targets for the treatment of several neuropsychiatric disorders, including Parkinson's disease, schizophrenia, some drug use addictions, as well as depression. Dopamine receptors are widely distributed in various regions of the brain, but their role and exact contribution to neuropsychiatric diseases has not yet been thoroughly studied. Based on the types of dopamine receptors and their distribution in different brain regions, this paper reviews the current research status of the molecular, cellular and circuit mechanisms of dopamine and its receptors involved in depression. Multiple lines of investigation of these mechanisms provide a new future direction for understanding the etiology and treatment of depression and potential new targets for antidepressant treatments.
Copyright © 2022 Zhao, Cheng, Piao, Cui and Li.

Entities:  

Keywords:  brain regions; dopamine receptors; neural circuits; pathogenesis of depression; signaling pathway

Year:  2022        PMID: 36059987      PMCID: PMC9428607          DOI: 10.3389/fphar.2022.947785

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.988


  242 in total

1.  A meta-analysis of dopamine use in hypotensive preterm infants: blood pressure and cerebral hemodynamics.

Authors:  S Sassano-Higgins; P Friedlich; I Seri
Journal:  J Perinatol       Date:  2011-01-27       Impact factor: 2.521

2.  βCaMKII in lateral habenula mediates core symptoms of depression.

Authors:  Kun Li; Tao Zhou; Lujian Liao; Zhongfei Yang; Catherine Wong; Fritz Henn; Roberto Malinow; John R Yates; Hailan Hu
Journal:  Science       Date:  2013-08-30       Impact factor: 47.728

Review 3.  Depression.

Authors:  Gin S Malhi; J John Mann
Journal:  Lancet       Date:  2018-11-02       Impact factor: 79.321

4.  D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor.

Authors:  Christopher H So; George Varghese; Kevin J Curley; Michael M C Kong; Mohammed Alijaniaram; Xiaodong Ji; Tuan Nguyen; Brian F O'dowd; Susan R George
Journal:  Mol Pharmacol       Date:  2005-05-27       Impact factor: 4.436

Review 5.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

Review 6.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

7.  Dopamine receptor gene expression in human amygdaloid nuclei: elevated D4 receptor mRNA in major depression.

Authors:  Lianbin Xiang; Katalin Szebeni; Attila Szebeni; Violetta Klimek; Craig A Stockmeier; Beata Karolewicz; John Kalbfleisch; Gregory A Ordway
Journal:  Brain Res       Date:  2008-02-14       Impact factor: 3.252

8.  A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.

Authors:  Mahino Fatima; Mir Hilal Ahmad; Saurabh Srivastav; Moshahid Alam Rizvi; A C Mondal
Journal:  Neurochem Int       Date:  2020-03-19       Impact factor: 3.921

Review 9.  Neuromodulation of hippocampal long-term synaptic plasticity.

Authors:  Jon Palacios-Filardo; Jack R Mellor
Journal:  Curr Opin Neurobiol       Date:  2018-09-10       Impact factor: 6.627

10.  3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.

Authors:  Masato Asanuma; Ikuko Miyazaki
Journal:  BMC Neurosci       Date:  2016-07-25       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.